Stoke Therapeutics, Inc. — Director's Dealing 2021

Mar 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Stoke Therapeutics, Inc. (STOK)
CIK: 0001623526
Period of Report: 2021-03-01

Reporting Person: LEVIN ARTHUR A (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-01	Common Stock	M	2776	$0.40	Acquired	2776	Direct
2021-03-01	Common Stock	M	1842	$0.40	Acquired	4618	Direct
2021-03-01	Common Stock	M	7882	$0.60	Acquired	12500	Direct
2021-03-01	Common Stock	S	7543	$60.5534	Disposed	4957	Direct
2021-03-01	Common Stock	S	4957	$61.1432	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-01	Director Stock Option (Right to Buy)	$0.40	M	2776	Disposed	2026-02-11	Common Stock (2776)	Direct
2021-03-01	Director Stock Option (Right to Buy)	$0.40	M	1842	Disposed	2027-02-02	Common Stock (1842)	Direct
2021-03-01	Director Stock Option (Right to Buy)	$0.60	M	7882	Disposed	2028-04-02	Common Stock (7882)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	17979	Indirect

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.89 to $60.88 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.90 to $61.80 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The option is 100% vested and exercisable.

F5: The option vested as to 1/48th of the total shares on February 28, 2018, and then 1/48th of the total shares vest at the end of each month thereafter, subject to the reporting person's continued service to the issuer through each vesting date.